London, April 22, 2026, 19:09 BST
GSK plc bought 335,000 ordinary shares on Tuesday as part of its existing share buyback, a U.S. securities filing showed, adding to a cash-return programme that is nearing its scheduled finish before next week’s earnings. BNP Paribas executed the purchases at 2,074p to 2,130p, with a volume-weighted average price — an average weighted by trade size — of 2,103.08p. The shares will be held in treasury, meaning GSK owns them but they do not count as public voting shares.
The timing matters. GSK has said purchases under the fourth tranche of the buyback are expected to be completed by April 24, while the company is due to report first-quarter results at 0700 BST on April 29. Buybacks can support earnings per share by reducing the share count, but investors will still be looking for cleaner signs of sales growth.
The market was not treating the latest buyback as a fix. GSK shares closed down 0.34% at 2,075p in London on Wednesday after falling 2.89% a day earlier; the FTSE 100 ended Wednesday down 0.21%.
Company-compiled analyst consensus, effective April 16, points to first-quarter turnover of 7.58 billion pounds, including 3.23 billion pounds from Specialty Medicines, 2.03 billion pounds from Vaccines and 2.32 billion pounds from General Medicines. For 2026, GSK expects turnover to rise 3% to 5% at constant exchange rates, which strip out currency swings, and core earnings per share to grow 7% to 9%.
Chief Executive Luke Miels, who took over in January, has framed 2026 as a year of execution rather than a reset. In February, he told reporters GSK needed “to accelerate what we have” and add through “smart business development,” while Sheena Berry, healthcare analyst at Quilter Cheviot, called the outlook a “steady and credible start” for him. Reuters
Analysts are still split on the pace of that delivery. Jefferies analyst Michael Leuchten highlighted a “4Q Sales 2% beat” in February but said guidance suggested possible consensus cuts because of foreign-exchange pressure, while Derren Nathan, head of equity research at Hargreaves Lansdown, wrote that GSK had “plenty of pipeline catalysts to watch out for” but that some timelines had moved further out. Investing
Recent product news has helped keep the pipeline in view. On Monday, GSK said China’s drug regulator approved Blenrep with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least one prior therapy. Hesham Abdullah, GSK’s global head of oncology R&D, said the approval brought anti-BCMA therapy — treatment targeting B-cell maturation antigen on myeloma cells — to patients in China with the disease.
The company is also spending to widen its respiratory and immunology business. GSK last week completed its $950 million acquisition of 35Pharma, adding HS235, an early-stage pulmonary hypertension drug candidate. Pulmonary hypertension is high blood pressure in the lungs; GSK’s Kaivan Khavandi said HS235 was “an important addition” to a pipeline aimed at chronic inflammatory and fibrotic diseases. GSK
The competitive backdrop is not soft. In pulmonary hypertension, Reuters has noted that current treatments include Merck’s injectable Winrevair. In respiratory disease, GSK’s Nucala sits in a field where Sanofi and Regeneron’s Dupixent is already approved for chronic obstructive pulmonary disease, a lung condition that restricts airflow.
But the buyback has limits. GSK has warned that foreign exchange is expected to cut first-quarter sales by about 3% to 4%, and that R&D spending will grow ahead of sales as it invests in the pipeline. If currency moves bite harder, vaccine demand weakens, or early-stage assets such as HS235 take longer to prove themselves, the per-share benefit from buying stock may not be enough to change the market’s view.
Next week’s results will therefore carry more weight than Wednesday’s filing. The question is whether Miels can show that capital returns, new approvals and bolt-on deals are moving in the same direction — before investors start treating the buyback as a cushion, not a catalyst.
